The purpose of this pilot/feasibility study was to evaluate the use of insulin regimens among individuals with poorly controlled type 2 diabetes. In addition, a secondary aim was to build the body of evidence regarding the use of insulin pumps in patients with type 2 diabetes.
Methods
The setting was a suburban private endocrinology practice. Patients were a convenience sample of 15 adults, aged 40 to 64 years with poorly controlled type 2 diabetes, as defined by a hemoglobin A1C (A1C) of 8% or higher when continuous subcutaneous insulin infusion (CSII) was initiated. Baseline, 3-month, 6-month, and 1-year A1C, body mass index (BMI), basal and bolus insulin use, and number of office visits were collected through medical record review. Descriptive, independent, and paired t tests were used to evaluate data.
Results
A significant reduction in basal insulin use was found. Significant reductions in A1Cs were found at 3 months, 6 months, and 1 year. A significant increase in BMI was noted.
Conclusions
Results indicated improvement in glycemic control with CSII for some patients with an associated increase in BMI. Reduction of basal insulin use was significant and, for some, cost effective using CSII. Current policies regarding CSII use in patients with type 2 diabetes need to be re-evaluated.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association.Diabetes statistics . Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/ . Accessed November 3, 2009.
2.
Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28(7): 1568-1573.
3.
Gray A., Clarke P., Farmer A., Holman R.Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ. 2002;325(7369):860. Available at: http://www.bmj.com/cgi/reprint/325/7369/860. Accessed November 3, 2009.
4.
Shichiri M., Kishikawa H., Ohkubo Y., Wake N.Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.
5.
Minshall ME, Roze S., Palmer AJ, et al. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clin Ther. 2005;27(6):940-950.
6.
Robard HW, Blonde L., Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice. 2007;13(Suppl 1):1-68.
7.
Boyle MEOptimizing the treatment of type 2 diabetes using current and future insulin technologies. Medsurg Nurs. 2008;17(6):383-390.
8.
Berthe E., Lireux B., Coffin C., et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39:224-229.
9.
Hsu SR, Lin SD, Tu STMetabolic control with insulin pump therapy: preliminary experience. J Chin Med Assoc. 2008;71(7): 353-356.
10.
Monami M., Lamanna C., Marchionni N., Mannucci E.Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes.2009;117(5):220-222.
11.
Nielsen S., Kain D., Szudzik E., Dhindsa S., Garg R., Dandona P.Use of continuous subcutaneous insulin infusion pump in patients with type 2 diabetes mellitus. Diabetes Educ. 2005;31(6):843-848.
12.
Raskin P., Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26(9):2598-2603.
13.
Wainstein J. , Metzger M., Boaz M., et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med.2005;22:1037-1046.
14.
Wainstein J. , Metzger M., Wexler ID, Cohen J., Raz I.The use of continuous insulin delivery systems in severely insulin-resistant patients [letter]. Diabetes Care. 2001;24(7):1299.
15.
Centers for Medicare and Medicaid Services.Infusion Pumps: C-peptide Levels as a Criterion for Use . Medicare National Coverage Determinations Manual: Coverage Determinations, revisions27, 280.14infusion pumps.CMS publication 100-03. Baltimore, Maryland: Centers for Medicare and Medicaid Services, US Department of Health and Human Services; 2005 .
16.
Sari R., Balci MKRelationship between C peptide and chronic complications in type 2 diabetes mellitus. J Natl Med Assoc. 2005;97(8):1113-1118.
17.
Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71-79.
18.
Pickup JC, Renard E.Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care. 2008;31(Suppl 2):S140-S145.
19.
American Diabetes Association.Economic costs of diabetes in the U.S. in 2007. Diabetes Care . 2008;31(3):596-615.
20.
Wagner EH, Sandhu N., Newton KM, McCulloch DK, Ramsey SD, Grothaus LCEffect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-189.
21.
Pelletier EM , Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall MEDirect medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy. 2008;6 (2-3):103-112.
22.
Potti LG, Haines ST, et al. Continuous subcutaneous insulin infusion therapy: a primer on insulin pumps. J Am Pharm Assoc.2009;49:e1-e17.
23.
Zhou H., Isaman DJ, Messinger S., et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care. 2005;28(12):2856-2863.
24.
Henry R., Gumbiner B., Ditzler T., et al. Intensive conventional insulin therapy for type 2 diabetes: metabolic effects during a 6 month outpatient trial. Diabetes Care. 1993;16:21-27.
25.
Kanakis SJ, Watts C., Leichter SBThe business of insulin pumps in diabetes care: clinical and economic considerations . Clinical Diabetes. 2002;20(4):214-216.
26.
Neumiller JJ , Odegard PS, Wysham CHUpdate on insulin management of type 2 diabetes . Diabetes Spectrum.2009;22(2):85-91.
27.
Renner R., Pfützner A., Trautmann M., et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care. 1999;22(5):784-788.
28.
Melki V., Renard E., Lassmann-Vague V., et al. Improvement of HbA1C and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998;21(6): 977-982.
